Comprehensive Coagulation Management in Cardiac Surgery: Anticoagulants, Heparin Resistance, Monitoring, and Bleeding Risks : Coagulation Management in Cardiac Surgery.
Research article published in Galen medical journal (2025)
Abstract
Effective coagulation management is pivotal to optimizing outcomes in cardiac surgery, influencing bleeding risk, transfusion requirements, and overall perioperative safety. This comprehensive review examines current strategies, limitations, and emerging innovations across anticoagulant use, coagulation monitoring, and bleeding management. Unfractionated heparin remains the standard for cardiopulmonary bypass (CPB) anticoagulation, owing to its rapid reversibility, though challenges such as heparin resistance persist. Alternatives including low molecular weight heparins, direct thrombin inhibitors, and novel oral anticoagulants are reserved for select indications and carry specific limitations. Perioperative coagulation monitoring is essential; tools such as activated clotting time (ACT), anti-factor Xa assays, and viscoelastic tests (e.g., thromboelastography [TEG] and rotational thromboelastometry [ROTEM]) guide targeted therapy. Despite these advances, bleeding remains common due to factors including preoperative antithrombotic therapy, CPB-induced coagulopathy, and postoperative hemostatic deficits. Management strategies center on prophylactic antifibrinolytics, individualized transfusion protocols, and the judicious use of reversal agents. Emerging frontiers including machine learning-enhanced viscoelastic algorithms, targeted antithrombotics (e.g., factor XI inhibitors), AI-based bleeding prediction, and gene therapy for inherited coagulopathies promise to personalize and improve care. Continued research is warranted to validate novel therapies and refine evidence-based protocols for coagulation management in cardiac surgery. Effective coagulation management is pivotal to optimizing outcomes in cardiac surgery, influencing bleeding risk, transfusion requirements, and overall perioperative safety. This comprehensive review examines current strategies, limitations, and emerging innovations across anticoagulant use, coagulation monitoring, and bleeding management. Unfractionated heparin remains the standard for cardiopulmonary bypass (CPB) anticoagulation, owing to its rapid reversibility, though challenges such as heparin resistance persist. Alternatives including low molecular weight heparins, direct thrombin inhibitors, and novel oral anticoagulants are reserved for select indications and carry specific limitations. Perioperative coagulation monitoring is essential; tools such as activated clotting time (ACT), anti-factor Xa assays, and viscoelastic tests (e.g., thromboelastography [TEG] and rotational thromboelastometry [ROTEM]) guide targeted therapy. Despite these advances, bleeding remains common due to factors including preoperative antithrombotic therapy, CPB-induced coagulopathy, and postoperative hemostatic deficits. Management strategies center on prophylactic antifibrinolytics, individualized transfusion protocols, and the judicious use of reversal agents. Emerging frontiers including machine learning–enhanced viscoelastic algorithms, targeted antithrombotics (e.g., factor XI inhibitors), AI-based bleeding prediction, and gene therapy for inherited coagulopathies promise to personalize and improve care. Continued research is warranted to validate novel therapies and refine evidence-based protocols for coagulation management in cardiac surgery.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Comprehensive Coagulation Management in Cardiac Surgery: Anticoagulants, Heparin Resistance, Monitoring, and Bleeding Risks : Coagulation Management in Cardiac Surgery.
Why This Matters for Hirudotherapy
This comprehensive review surveys coagulation management in cardiac surgery, describing unfractionated heparin as the standard for cardiopulmonary-bypass anticoagulation (noting persistent heparin resistance), alternatives such as low-molecular-weight heparins, direct thrombin inhibitors and novel oral anticoagulants for select indications, monitoring tools (ACT, anti-factor Xa assays, and viscoelastic tests like TEG/ROTEM), and emerging directions including factor XI inhibitors and AI-based bleeding prediction. For ASH it is useful context because it maps the clinical anticoagulant and hemostatic-monitoring terrain in which direct thrombin inhibitors—the drug class to which the leech-derived anticoagulant hirudin and its synthetic descendants (e.g., bivalirudin, lepirudin) belong—are deployed and measured. As a narrative review summarizing existing strategies rather than reporting new data, it provides framing and does not itself establish any leech-related or comparative-efficacy claim; it also does not address hirudotherapy directly.
Citation
Comprehensive Coagulation Management in Cardiac Surgery: Anticoagulants, Heparin Resistance, Monitoring, and Bleeding Risks : Coagulation Management in Cardiac Surgery.
Negargar et al. · Galen medical journal, 2025
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026